Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00196
|
|||||
Drug Name |
Rifampicin
|
|||||
Synonyms |
1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI); AZT + Rifampin; Abrifam; Archidyn; Arficin; Arzide; BA-41166E; Ba 41166; Ba 41166/E; Benemicin; Benemycin; DRG-0109; Dione 21-acetate; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; RFP; RMP; Ramp; Reserpine & Rifampicin; Rifa; Rifadin; Rifadin (TN); Rifadin I.V; Rifadin I.V.; Rifadin, Rimactane, Rifampicin, Rifampin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamicin AMP; Rifamor; Rifampicin; Rifampicin & EEP; Rifampicin & Propolis; Rifampicin (JP15/INN); Rifampicin SV; Rifampicin[INN:BAN:JAN]; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifampin (USP); Rifampin [USAN]; Rifamsolin; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactan (TN); Rimactane; Rimactane (TN); Rimactazid; Rimactizid; Rimazid; Rimycin; Rimycin (TN); Sinerdol; Sinerdol (TN); Tubocin; Tubocin (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Tuberculosis [ICD11: 1B1Z] | Approved | [1] | |||
Therapeutic Class |
Antituberculosis Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C43H58N4O12
|
|||||
Canonical SMILES |
CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C
|
|||||
InChI |
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
|
|||||
InChIKey |
JQXXHWHPUNPDRT-WLSIYKJHSA-N
|
|||||
CAS Number |
CAS 13292-46-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 822.9 | Topological Polar Surface Area | 220 | ||
Heavy Atom Count | 59 | Rotatable Bond Count | 5 | |||
Hydrogen Bond Donor Count | 6 | Hydrogen Bond Acceptor Count | 15 | |||
XLogP |
4.9
|
|||||
PubChem CID | ||||||
ChEBI ID |
ChEBI:28077
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [4] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [5] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [6] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | OATP1B1 | Transporter Info | Km = 1.5 microM | Human cervical cancer cell line (Hela)-OATP1B1 | [4] | |
OATP1B1 | Transporter Info | Km = 13 microM | Oocytes-OATP1B1 | [5] | ||
OATP1B3 | Transporter Info | Km = 2.3 microM | Oocytes-OATP1B3 | [5] | ||
References | ||||||
1 | Rifampicin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26. | |||||
3 | Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43. | |||||
4 | Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. | |||||
5 | Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72. | |||||
6 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.